Trial Profile
Study of GSK2302024A Antigen-Specific Cancer Immunotherapeutic Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 2302024A (Primary) ; Aromatase inhibitors; Carboplatin; Cyclophosphamides; Docetaxel; Doxorubicin; Epirubicin; Exemestane; Fluorouracil; Letrozole; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
- Acronyms INDUCT; NEOADJ
- Sponsors GlaxoSmithKline; GSK
- 14 May 2019 This trial has been discontinued in UK as per European Clinical Trials Database record.
- 24 Sep 2014 Status changed from recruiting to discontinued, as per ClinicalTrials.gov record.
- 29 Apr 2014 New source identified and integrated (M.D. Anderson Cancer Center: 2013-0418).